Skip to main content
Erschienen in: Supportive Care in Cancer 5/2005

01.05.2005 | Original Article

Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports

verfasst von: Jo Caers, Christel Fontaine, Vincent Vinh-Hung, Johan De Mey, Gerrit Ponnet, Chris Oost, Jan Lamote, Jacques De Greve, Benjamin Van Camp, Patrick Lacor

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

Aims

The use of subcutaneous infusion ports has become standard practice to provide a long-term venous access in oncological patients. The aim of this retrospective study was to assess the different complications of infusion ports in our population and to identify predisposing factors.

Patients and methods

We reviewed the medical records of 437 patients who were followed at the Oncology/Haematology Department of our hospital. Of these patients, there were 370 (84.4%) with solid tumours and 58 (13.2%) with haematological disease. The position of the catheter tip was evaluated by reviewing the available chest radiographs or phlebographies.

Main results

Analysis of the records showed that 346 patients (79.17%) had no complications. The most common complications after implantation were thrombosis (8.46%), catheter dysfunction (4.8%) and infections (4.4%). Univariate and multivariate analysis showed that catheter tip positioning was the most important predisposing risk factor for thrombosis. Catheter tips positioned in the brachiocephalic vein or in the cranial part of the superior vena cava were associated with a high risk of thrombosis. Other significant risk factors were gender and initial diagnosis. Female patients and patients with lung cancer also had an elevated risk of developing a thrombosis.

Conclusions

Compared to other reports, we noted a higher rate of thrombosis and port dysfunction. Since catheter tip position was a predisposing factor for developing a thrombosis, correct catheter position has to be ensured during placement. Prophylactic antithrombotic treatment might be beneficial in the event of failure to position the catheter correctly.
Literatur
1.
Zurück zum Zitat Anderson AJ, Krasnow SH, Boyer MW, Cutler DJ, Jones BD, Citron ML, Ortega LG, Cohen MH (1989) Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest 95:71–75PubMed Anderson AJ, Krasnow SH, Boyer MW, Cutler DJ, Jones BD, Citron ML, Ortega LG, Cohen MH (1989) Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest 95:71–75PubMed
2.
Zurück zum Zitat Barrios CH, Zuke JE, Blaes B, Hirsch JD, Lyss AP (1992) Evaluation of an implantable venous access system in a general oncology population. Oncology 49:474–478PubMed Barrios CH, Zuke JE, Blaes B, Hirsch JD, Lyss AP (1992) Evaluation of an implantable venous access system in a general oncology population. Oncology 49:474–478PubMed
3.
Zurück zum Zitat Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 112:423–428PubMed Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 112:423–428PubMed
4.
Zurück zum Zitat Biffi R, de Braud F, Orsi F, Pozzi S, Mauri S, Goldhirsch A, Nole F, Andreoni B (1998) Totally implantable venous access ports for long term chemotherapy. Ann Oncol 9:767–773CrossRefPubMed Biffi R, de Braud F, Orsi F, Pozzi S, Mauri S, Goldhirsch A, Nole F, Andreoni B (1998) Totally implantable venous access ports for long term chemotherapy. Ann Oncol 9:767–773CrossRefPubMed
5.
Zurück zum Zitat Boraks P, Seale J, Price J, Bass G, Ethell M, Keeling D, Mahendra P, Baglin T, Marcus R (1998) Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 101:483–486CrossRefPubMed Boraks P, Seale J, Price J, Bass G, Ethell M, Keeling D, Mahendra P, Baglin T, Marcus R (1998) Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 101:483–486CrossRefPubMed
6.
Zurück zum Zitat Brown-Smith JK, Stoner MH, Barley ZA (1990) Tunnelled catheter thrombosis: factors related to incidence. Oncol Nurs Forum 17:543–549PubMed Brown-Smith JK, Stoner MH, Barley ZA (1990) Tunnelled catheter thrombosis: factors related to incidence. Oncol Nurs Forum 17:543–549PubMed
7.
Zurück zum Zitat Chevrel JP, Destable MD, Breau JL, Dilin C (1988) Boitiers de perfusion implantables. Presse Med 17:17–20PubMed Chevrel JP, Destable MD, Breau JL, Dilin C (1988) Boitiers de perfusion implantables. Presse Med 17:17–20PubMed
8.
Zurück zum Zitat De Cicco M, Matovic M, Balestreri L, De Angelis V, Fracasso A, Morassut S, Coran F, Babare R, Buonadonna A, Testa V (1995) Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer patients. Thromb Res 78:127–137CrossRefPubMed De Cicco M, Matovic M, Balestreri L, De Angelis V, Fracasso A, Morassut S, Coran F, Babare R, Buonadonna A, Testa V (1995) Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer patients. Thromb Res 78:127–137CrossRefPubMed
9.
Zurück zum Zitat De Cicco M, Matovic M, Balestreri L, Panarello G, Fantin D, Morassut S, Testa V (1997) Central venous thrombosis: an early and frequent complication in cancer patients bearing long term silastic catheter. A prospective study. Thromb Res 86:101–113CrossRefPubMed De Cicco M, Matovic M, Balestreri L, Panarello G, Fantin D, Morassut S, Testa V (1997) Central venous thrombosis: an early and frequent complication in cancer patients bearing long term silastic catheter. A prospective study. Thromb Res 86:101–113CrossRefPubMed
10.
Zurück zum Zitat Debets JM, Wils JA, Schlangen JT (1995) A rare complication of implanted central venous access devices: catheter fracture and embolization. Support Care Cancer 3:432–434PubMed Debets JM, Wils JA, Schlangen JT (1995) A rare complication of implanted central venous access devices: catheter fracture and embolization. Support Care Cancer 3:432–434PubMed
11.
Zurück zum Zitat Devie-Hubert I, Carlier M, Pozzo Di Borgo C (1996) Les thromboses veineuses sur catheter central en cancerologie. Rev Med Interne 17:821–825PubMed Devie-Hubert I, Carlier M, Pozzo Di Borgo C (1996) Les thromboses veineuses sur catheter central en cancerologie. Rev Med Interne 17:821–825PubMed
12.
Zurück zum Zitat Eastridge BJ, Lefor AT (1995) Complications of indwelling venous access devices in cancer patients. J Clin Oncol 13:233–238PubMed Eastridge BJ, Lefor AT (1995) Complications of indwelling venous access devices in cancer patients. J Clin Oncol 13:233–238PubMed
13.
Zurück zum Zitat Guenier C, Nogaret JM, Ferreira J, Lorent I, Pector JC (1990) Voies d’abord veineux en oncologie par chambe implantable. Ann Chir 44:388–391PubMed Guenier C, Nogaret JM, Ferreira J, Lorent I, Pector JC (1990) Voies d’abord veineux en oncologie par chambe implantable. Ann Chir 44:388–391PubMed
14.
Zurück zum Zitat Horne MK 3rd, May DJ, Alexander HR, Steinhaus EP, Whitman ED, Chang RC, Doppman JL (1995) Venographic surveillance of tunnelled venous access devices in adult oncology patients. Ann Surg Oncol 2:174–178PubMed Horne MK 3rd, May DJ, Alexander HR, Steinhaus EP, Whitman ED, Chang RC, Doppman JL (1995) Venographic surveillance of tunnelled venous access devices in adult oncology patients. Ann Surg Oncol 2:174–178PubMed
15.
Zurück zum Zitat Kock HJ, Pietsch M, Krause U, Wilke H, Eigler FW (1998) Implantable vascular access systems: experience in 1500 patients with totally implanted central venous port systems. World J Surg 22:12–16 Kock HJ, Pietsch M, Krause U, Wilke H, Eigler FW (1998) Implantable vascular access systems: experience in 1500 patients with totally implanted central venous port systems. World J Surg 22:12–16
16.
Zurück zum Zitat Lagro SW, Verdonck LF, Borel Rinkes IH, Dekker AW (2000) No effect of nadroparin prophylaxis in the prevention of central venous catheter (CVC)-associated thrombosis in bone marrow transplant recipients. Bone Marrow Transplant 26:1103–1106CrossRefPubMed Lagro SW, Verdonck LF, Borel Rinkes IH, Dekker AW (2000) No effect of nadroparin prophylaxis in the prevention of central venous catheter (CVC)-associated thrombosis in bone marrow transplant recipients. Bone Marrow Transplant 26:1103–1106CrossRefPubMed
17.
Zurück zum Zitat Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK (1985) Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 42:296–300PubMed Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK (1985) Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 42:296–300PubMed
18.
Zurück zum Zitat Lokich JJ, Becker B (1983) Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer 52:1586–1589PubMed Lokich JJ, Becker B (1983) Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer 52:1586–1589PubMed
19.
Zurück zum Zitat Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, Chan AK, Andrew M (2003) An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res 109:101–108CrossRefPubMed Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, Chan AK, Andrew M (2003) An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res 109:101–108CrossRefPubMed
20.
Zurück zum Zitat Mismetti P, Mille D, Laporte S, Charlet V, Buchmuller-Cordier A, Jacquin JP, Fournel P, Dutrey-Dupagne C, Decousus H; CIP Study Group (2003) Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 88:67–73 Mismetti P, Mille D, Laporte S, Charlet V, Buchmuller-Cordier A, Jacquin JP, Fournel P, Dutrey-Dupagne C, Decousus H; CIP Study Group (2003) Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 88:67–73
21.
Zurück zum Zitat Monreal M, Lafoz E, Ruiz J, Valls R, Alastrue A (1991) Upper-extremity deep venous thrombosis and pulmonary embolism. A prospective study. Chest 99:280–283PubMed Monreal M, Lafoz E, Ruiz J, Valls R, Alastrue A (1991) Upper-extremity deep venous thrombosis and pulmonary embolism. A prospective study. Chest 99:280–283PubMed
22.
Zurück zum Zitat Monreal M, Raventos A, Lerma R, Ruiz J, Lafoz E, Alastrue A, Llamazares JF (1994) Pulmonary embolism in patients with upper extremity DVT associated to venous central lines—a prospective study. Thromb Haemost 72:548–550PubMed Monreal M, Raventos A, Lerma R, Ruiz J, Lafoz E, Alastrue A, Llamazares JF (1994) Pulmonary embolism in patients with upper extremity DVT associated to venous central lines—a prospective study. Thromb Haemost 72:548–550PubMed
23.
Zurück zum Zitat Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A (1996) Upper extremity deep venous thrombosis in cancer patients with venous access devices—prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75:251–253PubMed Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A (1996) Upper extremity deep venous thrombosis in cancer patients with venous access devices—prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75:251–253PubMed
24.
Zurück zum Zitat Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, Cozzi E (1982) Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery 92:706–712PubMed Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, Cozzi E (1982) Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery 92:706–712PubMed
26.
Zurück zum Zitat Puel V, Caudry M, Le Metayer P, Baste JC, Midy D, Marsault C, Demeaux H, Maire JP (1993) Superior vena cava thrombosis related to catheter malposition in cancer chemotherapy given through implanted ports. Cancer 72:2248–2252PubMed Puel V, Caudry M, Le Metayer P, Baste JC, Midy D, Marsault C, Demeaux H, Maire JP (1993) Superior vena cava thrombosis related to catheter malposition in cancer chemotherapy given through implanted ports. Cancer 72:2248–2252PubMed
27.
Zurück zum Zitat Puig-la Calle J Jr, Lopez Sanchez S, Piedrafita Serra E, Allende Honorato L, Artigas Raventos V, Puig la Calle J (1996) Totally implanted device for long-term intravenous chemotherapy: experience in 123 adult patients with solid neoplasms. J Surg Oncol 62:273–278CrossRefPubMed Puig-la Calle J Jr, Lopez Sanchez S, Piedrafita Serra E, Allende Honorato L, Artigas Raventos V, Puig la Calle J (1996) Totally implanted device for long-term intravenous chemotherapy: experience in 123 adult patients with solid neoplasms. J Surg Oncol 62:273–278CrossRefPubMed
28.
Zurück zum Zitat Schwarz RE, Groeger JS, Coit DG (1997) Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis. Cancer 79:1635–1640CrossRefPubMed Schwarz RE, Groeger JS, Coit DG (1997) Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis. Cancer 79:1635–1640CrossRefPubMed
29.
Zurück zum Zitat Stas M (1998) Positionering van katheter en poort, Poorten en Katheters voor langdurige I.V. therapie. Universitaire pers Leuven, Leuven Stas M (1998) Positionering van katheter en poort, Poorten en Katheters voor langdurige I.V. therapie. Universitaire pers Leuven, Leuven
Metadaten
Titel
Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports
verfasst von
Jo Caers
Christel Fontaine
Vincent Vinh-Hung
Johan De Mey
Gerrit Ponnet
Chris Oost
Jan Lamote
Jacques De Greve
Benjamin Van Camp
Patrick Lacor
Publikationsdatum
01.05.2005
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2005
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-004-0723-1

Weitere Artikel der Ausgabe 5/2005

Supportive Care in Cancer 5/2005 Zur Ausgabe

Forthcoming Meetings

Forthcoming Meetings 13/5

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.